Overall, the studies suggest that GLP‐1 RAs, particularly liraglutide(39, 40, 44, 45) and exenatide,(41, 42, 43, 46, 47) may have varying effects on bone metabolism and BMD in different populations, including T2D people and obese people, although the effect of the drugs is generally neutral. This evidence concerns the gene GCG and type 2 diabetes mellitus.